Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells.

[1]  Sai-Yang Zhang,et al.  A review of progress in o-aminobenzamide-based HDAC inhibitors with dual targeting capabilities for cancer therapy. , 2023, European journal of medicinal chemistry.

[2]  M. Tortorella,et al.  Molecular design of dual inhibitors of PI3K and potential molecular target of cancer for its treatment: A review. , 2021, European journal of medicinal chemistry.

[3]  Mariano J. Alvarez,et al.  Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses , 2021, British journal of haematology.

[4]  S. Keam,et al.  Umbralisib: First Approval , 2021, Drugs.

[5]  K. Ranganna,et al.  Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach , 2020, International journal of molecular sciences.

[6]  D. A. Rodrigues,et al.  Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol‐3‐kinase (PI3K): Current and Future Prospects , 2020, ChemMedChem.

[7]  S. Bai,et al.  CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action , 2020, Journal of cellular and molecular medicine.

[8]  A. Simeonov,et al.  Design, Synthesis and Biological Evaluation of Quinazolin-4-one Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. , 2020, Journal of medicinal chemistry.

[9]  D. A. Rodrigues,et al.  Design, Synthesis, and Pharmacological Evaluation of First‐in‐Class Multitarget N‐Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors , 2020, ChemMedChem.

[10]  S. Eschrich,et al.  Divergent Polypharmacology-Driven Cellular Activity of Structurally Similar Multi-Kinase Inhibitors through Cumulative Effects on Individual Targets. , 2019, Cell chemical biology.

[11]  A. Markham.  Alpelisib: First Global Approval , 2019, Drugs.

[12]  Xiaoguang Chen,et al.  Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases. , 2019, Journal of medicinal chemistry.

[13]  G. Madlambayan,et al.  Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia , 2019, Haematologica.

[14]  Jiajia Wang,et al.  Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma , 2019, Nagoya journal of medical science.

[15]  Rongshi Li,et al.  Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. , 2018, Journal of medicinal chemistry.

[16]  Hannah A. Blair.  Duvelisib: First Global Approval , 2018, Drugs.

[17]  Ewgenij Proschak,et al.  Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds. , 2018, Journal of medicinal chemistry.

[18]  Chang Kai Soh,et al.  Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma. , 2018, Journal of medicinal chemistry.

[19]  A. Markham.  Copanlisib: First Global Approval , 2017, Drugs.

[20]  T. Lu,et al.  Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2- c ]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors , 2017 .

[21]  B. Wagner,et al.  Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes , 2017, The Journal of Biological Chemistry.

[22]  M. Stiborová,et al.  Histone Deacetylase Inhibitors as Anticancer Drugs , 2017, International journal of molecular sciences.

[23]  E. Kebebew,et al.  Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases , 2017, Clinical Cancer Research.

[24]  T. Quan,et al.  PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer , 2017, Oncotarget.

[25]  Tiefeng Jin,et al.  Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC , 2016, Oncotarget.

[26]  A. Cavalli,et al.  Multitarget Drug Discovery and Polypharmacology , 2016, ChemMedChem.

[27]  F. Wang,et al.  Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities. , 2016, Journal of medicinal chemistry.

[28]  I. Flinn,et al.  Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. , 2016, The Lancet. Oncology.

[29]  Jean J. Zhao,et al.  PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting , 2014, Nature Reviews Cancer.

[30]  A. Markham.  Idelalisib: First Global Approval , 2014, Drugs.

[31]  J. Friedberg,et al.  PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo , 2014, Clinical Cancer Research.

[32]  R. Mathijssen,et al.  Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. , 2014, The Lancet. Oncology.

[33]  Shuxing Zhang,et al.  Polypharmacology: drug discovery for the future , 2013, Expert review of clinical pharmacology.

[34]  M. Voi,et al.  Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling , 2012, Clinical Cancer Research.

[35]  N. Brooijmans,et al.  Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[36]  J. McCubrey,et al.  The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology , 2010, Cancers.

[37]  J. Engelman,et al.  The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Abraham,et al.  Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. , 2010, Journal of medicinal chemistry.

[39]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[40]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[41]  L. Zhao,et al.  Class I PI3K in oncogenic cellular transformation , 2008, Oncogene.

[42]  Bert Vogelstein,et al.  The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations , 2007, Science.

[43]  M. P. Baker,et al.  Disposition of vorinostat, a novel histone deacetylase inhibitor and anticancer agent, in preclinical species. , 2007, Drug metabolism letters.

[44]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[45]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[46]  E. Sausville,et al.  Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Xiaodong Ma,et al.  Exploiting polypharmacology for improving therapeutic outcome of kinase inhibitors (KIs): An update of recent medicinal chemistry efforts. , 2018, European journal of medicinal chemistry.